Market news that you should not miss today
Market news that you should not miss today

Market news that you should not miss today

Karan Dsij Article rating: 4.1

Gufic Biosciences: The company has received permission from Central Drugs Standard Control Organisation, Ministry of Health & Family Welfare, New Delhi to manufacture & market Liposomal Amphotericin B injection 50 mg/vial (Lyophilised). The said injection is used to treat cases of Mucormycosis also called ‘Black Fungus’ that damages the nose, eyes, sinuses, and sometimes, even the brain.  

Unichem Laboratories soars over 7 per cent on getting nod for antidepressant tablets
Unichem Laboratories soars over 7 per cent on getting nod for antidepressant tablets

Unichem Laboratories soars over 7 per cent on getting nod for antidepressant tablets

Ganesh V Article rating: 5.0

Unichem Laboratories Limited today announced that it has received ANDA approval for its Amitriptyline HCI tablets from United States Food & Drug Administration (USFDA) to market a generic version of ELAVIL (Amitriptyline Hydrochloride) of AstraZeneca Pharmaceuticals LP.

NIIT venture StackRoute announces 2 programs in data science & machine learning
NIIT venture StackRoute announces 2 programs in data science & machine learning

NIIT venture StackRoute announces 2 programs in data science & machine learning

Apurva Joshi Article rating: 4.6

NIIT Limited’s venture StackRoute has announced the launch of Data Science Foundation Program and Advanced Post Graduate Programme (PGP) in data science & machine learning. StackRoute has designed these programs on data science track in partnership with Fraunhofer Institute for Intelligent Analysis & Information Systems (Germany).

In interaction with Niraj Kumar, Chief Investment Officer, Future Generali India Life Insurance Co. Ltd
In interaction with Niraj Kumar, Chief Investment Officer, Future Generali India Life Insurance Co. Ltd

In interaction with Niraj Kumar, Chief Investment Officer, Future Generali India Life Insurance Co. Ltd

Geyatee Deshpande Article rating: 3.8

Despite the second wave of the corona virus resulting in localised lockdowns across the country and creating an economic setback for businesses, Niraj Kumar, Chief Investment Officer, Future Generali India Life Insurance Co. Ltd., is quite optimistic about the overall scenario.

RSS
First21942195219621972199220122022203Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR